RBC Capital analyst Gregory Renza maintains $Perspective Therapeutics (CATX.US)$ with a buy rating, and adjusts the target price from $25 to $16.
According to TipRanks data, the analyst has a success rate of 46.3% and a total average return of 14.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Perspective Therapeutics (CATX.US)$'s main analysts recently are as follows:
Recent data shared by Perspective Therapeutics for VMT-alpha-NET showed an objective response rate (ORR) that fell short of expectations when compared to rivals. While there is potential for improved outcomes at increased dosage levels, reliable results are not anticipated until late-2025, following the potential FDA approval for advancing the trial to Cohort 3. Furthermore, initial findings for VMT01 in treating melanoma revealed complications related to kidney accumulation, which restricted dosage increments. These issues may continue to impact the company's stock until further studies potentially enhance the data available for VMT01.
Initial data from Cohort 1 and Cohort 2 of VMT-a-NET's phase I/IIa study reveals encouraging signals, alongside a need for patience in dose optimization. There appears to be a path to potential commerciality from Perspective's lead-specific chelator across its pipeline and platform.
The recent selloff in Perspective Therapeutics is seen as an overreaction to the early data from the dose escalation phase of the VMT-alpha-NET program. This data showed clinical activity that corresponds with dose intensity and presented a clean safety profile, which supports further dose escalation. There is a recommendation to consider buying on this weakness, especially with Perspective trading near cash levels.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
